Octocrylene Restriction in Cosmetic Products Placed in the European Union
In 2019, the European Commission established a priority list of potential endocrine disruptors. Octocrylene was one of the ingredients on that list and the SCCS was asked to assess its safety. The European Cosmetics Regulation will be amended in accordance with the SCCS conclusions in such assessment.


Octocrylene is a substituted acrylate and is used as a light stabilizer, UV absorber and UV filter in cosmetic and personal care products.

According to the Cosmetics Regulation (No. 1223/2009), Octocrylene is included in the list of UV filters allowed in cosmetic products (Annex VI, entry 10). Octocrylene is allowed up to a concentration of 10% (as acid) in cosmetic products, as an UV filter.

In early 2019, a priority list of 28 potential endocrine disruptors (not already covered by the bans of cosmetic regulation) was established by the Commission. From these 28 substances, 14 were considered as higher priority (Group A), which included Octocrylene. The European Commission’s Scientific Committee on Consumer Safety (SCCS) was asked to assess the safety of these ingredients. Stakeholders submitted scientific evidence (during the call for data) aiming to demonstrate the safety of Octocrylene as UV filters in cosmetic products.

In March this year, the SCCS published its opinion on Octocrylene. Considering the concerns related to its potential endocrine disrupting properties, the SCCS concluded that Octocrylene is safe as a UV-filter at concentrations up to 10% in cosmetic products when used individually. Octocrylene was also considered safe for a combined use of sunscreen cream or lotion, sunscreen pump spray, face cream, hand cream and lipstick at a concentration up to 10% (in line with current restrictions). However, the SCCS concluded that Octocrylene at concentrations of 10% or above in sunscreen propellant spray is not safe for the combined use. In such products, the Committee considers that Octocrylene is safe if its concentration does not exceed 9% when used together with face cream, hand cream and lipstick containing 10% Octocrylene.

The SCCS stated that “whilst there are indications from some in vivo studies to suggest that Octocrylene may have endocrine effects, the evidence is not conclusive enough at present to enable deriving a specific endocrine-related toxicological point of departure for use in safety assessment”.

Although contact sensitization to Octocrylene has been reported, the number of reported cases of allergic contact dermatitis seems to be negligible taking into account the widespread use of this ingredient. Photoallergy to Octocrylene is strongly related to previous photoallergy to topical ketoprofen.


In October 14th, the European Commission has communicated to the WTO (World Trade Organization) a draft Regulation to introduce new use restrictions for two UV filters (Octocrylene and Benzophenone-3).

Following the SCCS opinions, the European Commission states that “it can be concluded that there is a potential risk to human health arising from the use of Benzophenone-3 and Octocrylene as UV filters in cosmetic products in the concentrations currently allowed. Therefore, the use of Benzophenone-3 and Octocrylene should be restricted to the maximum concentrations proposed by the SCCS.“ Regulation (EC) No 1223/2009 will be amended accordingly.

In sum, the maximum concentration allowed for Octocrylene will be 9% (instead of 10%) in propellant spray products.

Reasonable periods of time will be granted to the industry in order to make the necessary adjustments to product formulations and comply with new requirements and withdraw cosmetic products which do not comply with those requirements.

The amendments to the Regulation will enter into force 20 days after its publication in the Official Journal of the European Union.

If you wish to get more information on this subject or others, feel free to contact us at info@criticalcatalyst.com.


  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.
  2. Scientific Committee on Consumer Safety (SCCS). Opinion on Octocrylene. SCCS/1627/21. 2021.


medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »